MedTrace Logo

Effects of Sugammadex and Conventional Reversal on Lung Function in Laparoscopic Abdominal Surgery

NCT06210165 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-01-18

No results posted yet for this study

Summary

The goal of this clincal trial is to determine the differences in few parameter of lung function (ie Forced Vital Capacity (FCV)) between Sugammadex and conventional reversal in laparoscopic abdominal surgery. The main questions it aims to answer are:

1. Is there differences in the pulmonary function test preoperative and post extubation between Sugammadex and conventional reversal in laparoscopic abdominal surgery?
2. Is there differences in the size of atelectasis area between Sugammadex and conventional reversal in laparoscopic abdominal surgery?
3. Is there differences between sugammadex and conventional reversal in postoperative mean length of stay in laparoscopic abdominal surgery?

Participants will be asked

1. to do baseline spirometry before operation
2. to be examined for lung ultrasound before operation
3. to be given either sugammadex or neostigmine as reversal after operation is completed
4. to repeat spirometry after operation for few times
5. to be examined for lung ultrasound after operation

Researcher will compare sugammadex group and conventional group to see if any difference in term of lung function, size of atelectasis and length of stay.

Conditions

  • Atelectasis, Postoperative
  • Pulmonary Function; Newborn, Abnormal

Interventions

DRUG

Sugammadex

IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery

DRUG

Neostigmine and atropine

IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery

Sponsors & Collaborators

  • Rhendra Hardy Mohamad Zaini

    lead OTHER

Principal Investigators

  • NIK MUHAMMAD 'AIZAT 'ADROS, MBBS · Hospital Universiti Sains Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-07
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210165 on ClinicalTrials.gov